tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| van den Berg JW et al. | New immunosuppressive drugs and lung transplantation: last or least? | 1999 | Thorax | pmid:10335012 |
| Shirbacheh MV et al. | Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. | 1999 | J. Pharmacol. Exp. Ther. | pmid:10336506 |
| Gold BG et al. | Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. | 1999 | J. Pharmacol. Exp. Ther. | pmid:10336507 |
| Steg RE et al. | Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. | 1999 | Bone Marrow Transplant. | pmid:10338054 |
| Ferrand-Drake M et al. | Mitochondrial permeability transition induced DNA-fragmentation in the rat hippocampus following hypoglycemia. | 1999 | Neuroscience | pmid:10338300 |
| Conboy IM et al. | Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:10339586 |
| Ma D and Carlow CK | Molecular characterization of FKBP13 from filarial parasites. | 1999 | Mol. Biochem. Parasitol. | pmid:10340490 |
| Ruddy SB et al. | Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. | 1999 | Int J Pharm | pmid:10341307 |
| Uchio E et al. | Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. | 1999 Mar-Apr | Clin. Exp. Rheumatol. | pmid:10342043 |
| Moffatt SD et al. | Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. | 1999 | Transplantation | pmid:10342309 |
| Khanna A et al. | Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow. | 1998 | Transpl. Immunol. | pmid:10342736 |
| Dresske B et al. | WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. | 1998 | Transpl. Immunol. | pmid:10342738 |
| Tacrolimus in the prevention of graft rejection: new indication. Helpful alternative to ciclosporin. | 1998 | Prescrire Int | pmid:10342948 | |
| Boehringer M et al. | Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin. | 1999 | Nephrol. Dial. Transplant. | pmid:10344407 |
| Siemann G et al. | Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. | 1999 | Mol. Pharmacol. | pmid:10347253 |
| Oddis CV et al. | Tacrolimus in refractory polymyositis with interstitial lung disease. | 1999 | Lancet | pmid:10347992 |
| Araki T et al. | Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation. | 1999 | Metab Brain Dis | pmid:10348311 |
| Möller A et al. | The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. | 1999 | Drug Metab. Dispos. | pmid:10348790 |
| Murata M et al. | A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. | 1999 | Br. J. Haematol. | pmid:10354150 |
| Zarifian A et al. | Cyclosporine-associated thrombotic microangiopathy in renal allografts. | 1999 | Kidney Int. | pmid:10354295 |
| Yang J et al. | Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506. | 1999 | Pathol. Int. | pmid:10355966 |
| Toung TJ et al. | Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. | 1999 | Stroke | pmid:10356112 |
| Muramatsu K et al. | Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. | 1999 | J Hand Surg Am | pmid:10357540 |
| Cheng HH et al. | Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase. | 1999 | J. Biol. Chem. | pmid:10358074 |
| Cao S et al. | Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. | 1999 | Pediatr Transplant | pmid:10359027 |
| Doolabh VB and Mackinnon SE | FK506 accelerates functional recovery following nerve grafting in a rat model. | 1999 | Plast. Reconstr. Surg. | pmid:10359255 |
| Johnson KL and Lawen A | Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. | 1999 | Immunol. Cell Biol. | pmid:10361256 |
| Gummert JF et al. | Newer immunosuppressive drugs: a review. | 1999 | J. Am. Soc. Nephrol. | pmid:10361877 |
| Kanoh S et al. | Effect of FK506 on ATP-induced intracellular calcium oscillations in cow tracheal epithelium. | 1999 | Am. J. Physiol. | pmid:10362712 |
| Jiang H et al. | Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. | 1999 | Transpl. Int. | pmid:10363590 |
| Venz S et al. | Contribution of color and power Doppler sonography to the differential diagnosis of acute and chronic rejection, and tacrolimus nephrotoxicity in renal allografts. | 1999 | Transpl. Int. | pmid:10363595 |
| Onsager DR et al. | Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. | 1999 | J. Heart Lung Transplant. | pmid:10363689 |
| Ito F et al. | FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. | 1999 | Arch. Dermatol. Res. | pmid:10367710 |
| Przepiorka D et al. | Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. | 1999 | Biol. Blood Marrow Transplant. | pmid:10371361 |
| Matzinger P | Graft tolerance: a duel of two signals. | 1999 | Nat. Med. | pmid:10371494 |
| Kirk AD et al. | Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. | 1999 | Nat. Med. | pmid:10371508 |
| Lieberman DN and Mody I | Properties of single NMDA receptor channels in human dentate gyrus granule cells. | 1999 | J. Physiol. (Lond.) | pmid:10373689 |
| Cox KL et al. | Paediatric liver transplantation: indications, timing and medical complications. | 1999 | J. Gastroenterol. Hepatol. | pmid:10382641 |
| Higgins RM et al. | Conversion between cyclosporin and tacrolimus--30-fold dose prediction. | 1999 | Nephrol. Dial. Transplant. | pmid:10383044 |
| Henry ML | Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. | 1999 | Clin Transplant | pmid:10383101 |
| Koski GK et al. | Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. | 1999 | J. Immunol. | pmid:10384103 |
| Leung W et al. | Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. | 1999 | Transplantation | pmid:10385092 |
| Squadrito F et al. | Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. | 1999 | Br. J. Pharmacol. | pmid:10385251 |
| Gerhardt U et al. | Blood pressure control in kidney transplant recipients: influence of immunosuppression. | 1999 | J Auton Pharmacol | pmid:10385269 |
| Liang H et al. | Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. | 1999 | J. Biol. Chem. | pmid:10391929 |
| Hasselder AS | The nursing management of a patient receiving Prograf as a primary immunosuppressive agent. | 1998 Apr-Jun | EDTNA ERCA J | pmid:10392057 |
| Horowitz MM et al. | Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. | 1999 | Biol. Blood Marrow Transplant. | pmid:10392964 |
| Kochi S et al. | Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. | 1999 | Eur. J. Pharmacol. | pmid:10395024 |
| Magee CC et al. | Immunosuppressive agents in organ transplantation. | 1999 | Hosp Med | pmid:10396414 |
| Gold BG et al. | Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. | 1999 | Neurosci. Lett. | pmid:10400242 |